Cannabigerol ATC code
E)-3,7-Dimethylocta-2,6-dienyl]-5-pentyl-benzene-1,3-diol CAS Number PubChem CID ChemSpider UNII ChEBI ChEMBL CompTox Dashboard ( EPA) Formula C 21 H 32 O 2 Molar mass g·mol 316.485 −1 3D model ( JSmol)
(what is this?) (verify)
Cannabigerol ( CBG) is one of more than 120 identified cannabinoid compounds found in the plant genus . Cannabis  Cannabigerol is the decarboxylated form of  cannabigerolic acid, the parent molecule from which other cannabinoids are synthesized. Cannabigerol is a minor constituent of cannabis. During plant growth, most of the cannabigerol is converted into other cannabinoids, primarily  tetrahydrocannabinol (THC) or cannabidiol (CBD), leaving about 1% cannabigerol in the plant. 
Biosynthesis of cannabigerol
biosynthesis of cannabigerol begins by loading hexanoyl-CoA onto a polyketide synthase assembly protein and subsequent condensation with three molecules of malonyl-CoA. This  polyketide is cyclized to olivetolic acid via olivetolic acid cyclase, and then prenylated with a ten carbon isoprenoid precursor, geranyl pyrophosphate, using an aromatic prenyltransferase enzyme, geranyl-pyrophosphate—olivetolic acid geranyltransferase, to biosynthesize cannabigerolic acid, which can then be decarboxylated to yield cannabigerol.  
As of 2019
clinical research has been conducted to test the specific effects of cannabigerol in humans. 
Cannabigerol is under
laboratory research to determine its pharmacological properties and potential effects in disease conditions.  Contrary to the major  psychoactive cannabinoid THC, cannabigerol antagonizes CB1 receptors and is both an α 2-adrenergic receptor agonist and moderate 5-HT 1A receptor antagonist.  Cannabigerol displays  CB1 and CB2 binding affinity,   and has been evaluated in laboratory models of  colitis. 
Cannabigerol is not scheduled by the UN
Convention on Psychotropic Substances. In the United States, CBG derived from cannabis is illegal under the Controlled Substances Act, while CBG derived from hemp is legal. 
ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A (2017). Phytochemistry of Cannabis sativa L. Progress in the Chemistry of Organic Natural Products. 103. pp. 1–36. doi: 10.1007/978-3-319-45541-9_1. ISBN . 978-3-319-45539-6 PMID 28120229.
Turner SE, Williams CM, Iversen L, Whalley BJ (2017). "Molecular Pharmacology of Phytocannabinoids". Progress in the Chemistry of Organic Natural Products. 103: 61–101. doi: 10.1007/978-3-319-45541-9_3. ISBN . 978-3-319-45539-6 PMID 28120231.
^ a b
Morales P, Reggio PH, Jagerovic N (2017). "An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol". Frontiers in Pharmacology. 8: 422. doi: . 10.3389/fphar.2017.00422 PMC . 5487438 PMID 28701957.
Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, et al. (February 2016). "Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes". Journal of Natural Products. 79 (2): 324–31. doi: 10.1021/acs.jnatprod.5b00949. PMID 26836472.
Gagne SJ, Stout JM, Liu E, Boubakir Z, Clark SM, Page JE (July 2012). "Identification of olivetolic acid cyclase from Cannabis sativa reveals a unique catalytic route to plant polyketides". Proceedings of the National Academy of Sciences of the United States of America. 109 (31): 12811–6. Bibcode: 2012PNAS..10912811G. doi: . 10.1073/pnas.1200330109 PMC . 3411943 PMID 22802619.
Fellermeier M, Zenk MH (May 1998). "Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol". FEBS Letters. 427 (2): 283–5. doi: . 10.1016/s0014-5793(98)00450-5 PMID 9607329. S2CID 7777284.
^ a b c d
"Cannabigerol; ID 5315659". PubChem, National Library of Medicine, US National Institutes of Health. 11 May 2019 . Retrieved . 12 May 2019
^ a b
Morales P, Hurst DP, Reggio PH (2017). "Molecular Targets of the Phytocannabinoids: A Complex Picture". Phytocannabinoids. Progress in the Chemistry of Organic Natural Products. 103. pp. 103–131. doi: 10.1007/978-3-319-45541-9_4. ISBN . 978-3-319-45539-6 PMC . 5345356 PMID 28120232.
Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG (January 2010). "Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist". British Journal of Pharmacology. 159 (1): 129–41. doi: 10.1111/j.1476-5381.2009.00515.x. PMC . 2823359 PMID 20002104.
^ Zagzoog A, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Sci Rep 2020; 10: 20405. doi: 10.1038/s41598-020-77175-y
Couch DG, Maudslay H, Doleman B, Lund JN, O'Sullivan SE (March 2018). "The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis" (PDF). Inflammatory Bowel Diseases. 24 (4): 680–697. doi: . 10.1093/ibd/izy014 PMID 29562280.
"USC > Title 21 > Chapter 13 > Subchapter I > Part A > § 802. Definitions: (16)" (PDF). Government Publishing Office - US Code. 2016.
This article is a direct transclusion of
the Wikipedia article and therefore may not meet the same editing standards as CannabisQAwiki.